** Shares of Mirum Pharmaceuticals rise 5.7% to $43.97
** Co raises 2024 rev. forecast to the range of $330 mln to $335 mln from its prior range of $310 mln to $320 mln
** Posts Q3 rev. of $90.3 mln, above analysts' est. of $82.0 mln - LSEG
** Reports Q3 loss per share of 30 cents, smaller than analysts' est. of 45 cents - LSEG
** Co's Livmarli, a liver disease drug, posts Q3 rev. of $59.1 mln, above analysts' est of $50 mln - LSEG
** All 11 brokerages covering MIRM rate the stock "buy" or higher; median PT is $65.50 - LSEG
** Stock has risen ~49% YTD, including session gains
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.